Phase I clinical trial with fractionated radioimmunotherapy using 131I-labeled chimeric G250 in metastatic renal cancer.

Unlabelled: This trial was performed to determine the maximum tolerated whole-body radiation-absorbed dose of fractionated (131)I-cG250.

Methods: This was a phase 1 dose escalation trial. Dose escalation refers here to the escalation of average whole-body absorbed dose.